Business, energy, technology, markets and global industry news from Business News Today

Datroway

PharmaDeviceNews Datroway
Pharma & Biotech

Summit Therapeutics has $2bn from AstraZeneca and stronger cancer survival data, but will the FDA approve ivonescimab?

Summit Therapeutics has secured a $2 billion strategic equity investment from AstraZeneca while expanding the global development programme for ivonescimab. However, the November 14 FDA decision remains uncertain because the original HARMONi overall-survival analysis did not achieve statistical significance, despite favourable results from subsequent analyses and separate Chinese trials.

Read More
Datroway’s European Union approval expands first-line treatment options for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for immunotherapy, following an overall survival benefit in the Phase 3 TROPION-Breast02 trial. Representative image.
Pharma & Biotech

Datroway EU approval expands first-line treatment options for metastatic triple-negative breast cancer

EU approval moves Datroway into first-line metastatic TNBC after TROPION-Breast02 showed survival gains, intensifying the TROP2 ADC race.

Read More
CHMP backs Datroway in first-line TNBC
Pharma & Biotech

Datroway nears EU first-line approval for metastatic triple-negative breast cancer

Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More